UK markets closed
NIKKEI 225
38,073.98 -128.42 (-0.34%) HANG SENG
18,537.81 +223.91 (+1.22%) CRUDE OIL
79.63 +0.37 (+0.47%) GOLD FUTURES
2,353.00 +12.70 (+0.54%) DOW
39,387.76 +331.36 (+0.85%) Bitcoin GBP
50,081.56 +1,109.21 (+2.26%)
BioCryst Pharmaceuticals, Inc. (BO1.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
At close: 01:30PM CEST
Currency in EUR
Valuation measures4
| Market cap (intra-day) | 979.09M |
| Enterprise value | 1.44B |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 2.87 |
| Price/book (mrq) | 55.19 |
| Enterprise value/revenue | 4.04 |
| Enterprise value/EBITDA | -14.12 |
Trading information
Stock price history
| Beta (5Y monthly) | 1.96 |
| 52-week change 3 | -37.88% |
| S&P500 52-week change 3 | 25.59% |
| 52-week high 3 | 8.2140 |
| 52-week low 3 | 3.8370 |
| 50-day moving average 3 | 4.5536 |
| 200-day moving average 3 | 5.4121 |
Share statistics
| Avg vol (3-month) 3 | 190 |
| Avg vol (10-day) 3 | 200 |
| Shares outstanding 5 | 206.38M |
| Implied shares outstanding 6 | 207.96M |
| Float 8 | 191.42M |
| % held by insiders 1 | 1.04% |
| % held by institutions 1 | 88.49% |
| Shares short 4 | N/A |
| Short ratio 4 | N/A |
| Short % of float 4 | N/A |
| Short % of shares outstanding 4 | N/A |
| Shares short (prior month ) 4 | N/A |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | N/A |
| Last split date 3 | N/A |
Financial highlights
Currency in USD.Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Mar 2024 |
Profitability
| Profit margin | -58.69% |
| Operating margin (ttm) | -15.62% |
Management effectiveness
| Return on assets (ttm) | -10.85% |
| Return on equity (ttm) | N/A |
Income statement
| Revenue (ttm) | 355.4M |
| Revenue per share (ttm) | 1.81 |
| Quarterly revenue growth (yoy) | 34.90% |
| Gross profit (ttm) | N/A |
| EBITDA | -82.09M |
| Net income avi to common (ttm) | -208.58M |
| Diluted EPS (ttm) | -1.0000 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 336.55M |
| Total cash per share (mrq) | 1.63 |
| Total debt (mrq) | 852.9M |
| Total debt/equity (mrq) | N/A |
| Current ratio (mrq) | 3.73 |
| Book value per share (mrq) | -2.31 |
Cash flow statement
| Operating cash flow (ttm) | -101.31M |
| Levered free cash flow (ttm) | -72.42M |
© 2024 Yahoo. All rights reserved.